GlobeNewswire: Cornerstone Pharmaceuticals, Inc. Contains the last 10 of 110 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T21:56:07ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/09/28/2524126/0/en/Cornerstone-Pharmaceuticals-Initiates-Phase-1-Trial-of-CPI-613-devimistat-in-Combination-with-Chemoradiation-for-the-Treatment-of-Advanced-Pancreatic-Cancer.html?f=22&fvtc=4&fvtv=20178Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer2022-09-28T11:00:00Z<![CDATA[Clinical program advancement represents key milestone for Cornerstone underscoring its commitment to the development of lead compound, devimistat, in pancreatic cancer Clinical program advancement represents key milestone for Cornerstone underscoring its commitment to the development of lead compound, devimistat, in pancreatic cancer]]>https://www.globenewswire.com/news-release/2022/08/03/2491342/0/en/Cornerstone-Pharmaceuticals-Announces-Successful-Completion-of-Phase-1b-Clinical-Trial-for-CPI-613-Devimistat-in-Combination-with-Gemcitabine-and-Cisplatin-in-Patients-with-Biliary.html?f=22&fvtc=4&fvtv=20178Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer2022-08-03T12:00:00Z<![CDATA[CRANBURY, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the successful completion of a Phase 1b clinical trial of CPI-613® (devimistat) in combination with gemcitabine and cisplatin for the treatment of advanced unresectable biliary tract cancer. In collaboration with Michigan Medicine, the Phase 1b study consisted of a multicenter trial of gemcitabine and cisplatin with devimistat as first-line therapy for patients with locally advanced unresectable or metastatic biliary tract cancer.]]>https://www.globenewswire.com/news-release/2022/07/06/2474899/0/en/Cornerstone-Pharmaceuticals-Strengthens-Scientific-Advisory-Board-with-the-Appointment-of-Distinguished-Scholar-Jason-Locasale-Ph-D.html?f=22&fvtc=4&fvtv=20178Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.2022-07-06T12:00:00Z<![CDATA[CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the appointment of Jason Locasale, Ph.D., as a member of the Company’s Scientific Advisory Board. Dr. Locasale is a highly respected scholar and brings to Cornerstone deep expertise in cancer metabolism, metabolomics, nutrition and the metabolic interface of epigenetics.]]>https://www.globenewswire.com/news-release/2022/06/27/2469477/0/en/Cornerstone-Pharmaceuticals-to-Present-Pancreatic-Cancer-Data-on-CPI-613-Devimistat-From-Its-Open-Label-Phase-1-Study-at-the-European-Society-of-Medical-Oncology-ESMO-World-Congres.html?f=22&fvtc=4&fvtv=20178Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 20222022-06-27T12:00:00Z<![CDATA[CRANBURY, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that data on its lead compound CPI-613® (devimistat) in combination with gemcitabine and nab-paclitaxel in patients with locally advanced or metastatic pancreatic cancer will be presented at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022, taking place June 29 through July 2, 2022 in Barcelona, Spain.]]>https://www.globenewswire.com/news-release/2022/06/16/2464300/0/en/Cornerstone-Pharmaceuticals-Announces-Published-Data-on-CPI-613-Devimistat-as-an-Effective-Approach-to-Targeting-Carcinoma-Catabolism-UPDATE.html?f=22&fvtc=4&fvtv=20178Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE2022-06-16T18:14:23Z<![CDATA[Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613® (devimistat) targeting carcinoma catabolism.]]>https://www.globenewswire.com/news-release/2022/06/01/2454159/0/en/Cornerstone-Pharmaceuticals-to-Present-Pancreatic-Cancer-Clear-Cell-Sarcoma-and-Biliary-Tract-Cancer-Research-Featuring-CPI-613-Devimistat-at-the-2022-American-Society-of-Clinical-.html?f=22&fvtc=4&fvtv=20178Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting2022-06-01T12:00:00Z<![CDATA[Cranbury, NJ, June 01, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the Company and its partners will present three abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3 – June 7, 2022 in Chicago.]]>https://www.globenewswire.com/news-release/2022/05/24/2449592/0/en/European-Medicines-Agency-Grants-Orphan-Drug-Designation-to-Cornerstone-Pharmaceuticals-CPI-613-Devimistat-for-Treatment-of-Patients-with-Advanced-Unresectable-Biliary-Tract-Cancer.html?f=22&fvtc=4&fvtv=20178European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer2022-05-24T15:04:15Z<![CDATA[Cranbury, NJ, May 24, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the European Medicines Agency (EMA) has granted orphan drug designation to CPI-613® (devimistat) for the treatment of advanced unresectable biliary tract cancer.]]>https://www.globenewswire.com/news-release/2022/05/19/2447011/0/en/Rafael-Pharmaceuticals-Inc-Announces-Corporate-Name-Change-to-Cornerstone-Pharmaceuticals-Inc.html?f=22&fvtc=4&fvtv=20178Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.2022-05-19T13:00:00Z<![CDATA[Company name change reflects mission to address significant unmet needs in rare cancer therapeutics, returning to company roots Company name change reflects mission to address significant unmet needs in rare cancer therapeutics, returning to company roots]]>https://www.globenewswire.com/news-release/2022/01/18/2368484/0/en/Rafael-Pharmaceuticals-Announces-Ongoing-Successful-Enrollment-and-Opening-of-Additional-Sites-for-Phase-2-Clinical-Trial-of-CPI-613-Devimistat-in-Combination-with-Gemcitabine-and-.html?f=22&fvtc=4&fvtv=20178Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer2022-01-18T13:30:00Z<![CDATA[CRANBURY, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, today announced the ongoing successful enrollment rate of its Phase 2 clinical trial for CPI-613® (devimistat) in combination with gemcitabine and cisplatin in patients with biliary tract cancer. The multicenter trial is for patients with locally advanced unresectable or metastatic biliary tract cancer who have had no prior treatment. The trial is currently open through The University of Michigan Health Rogel Cancer Center as an investigator-sponsored trial. The trial is also open at Fred Hutchinson Cancer Research Center and UT Southwestern Simmons Cancer Center. Rafael is also launching additional sites for the trial at Northwestern University Lurie Cancer Center, UH Seidman Cancer Center, The University of Arizona Cancer Center, University of Wisconsin Carbone Cancer Center, Vanderbilt-Ingram Cancer Center, Atlantic Health System Cancer Care, and Allegheny Health Network Cancer Institute.]]>https://www.globenewswire.com/news-release/2022/01/06/2362450/0/en/Rafael-Pharmaceuticals-Announces-Successful-Completion-of-Dose-Escalation-with-No-Dose-Limiting-Toxicity-DLT-in-First-Cohort-of-APOLLO-613-Phase-1-2-Clinical-Trial-of-CPI-613-Devim.html?f=22&fvtc=4&fvtv=20178Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma2022-01-06T13:30:00Z<![CDATA[Company Will Open Additional Sites and Has Begun Enrolling Patients in the Second Cohort of the Trial Company Will Open Additional Sites and Has Begun Enrolling Patients in the Second Cohort of the Trial]]>